Biotech Values

[DewDiligence]

Re: Randal Kirk

“I think he’s the great pharmaceutical salesman of our age,” says Harry M. Tracy, who runs the newsletter NeuroInvestment Research. Tracy argues Kirk is better at making money than developing medically important drugs. “When it’s Randal Kirk, he might be able to take a bad hand and do something with it,” he says. “Big money, not so big clinically.”

Tracy’s description is certainly apt with respect to Vyvanse and Viibryd, which are among the two most useless drugs to be approved in recent years, IMO.